SRZN has had good momentum. It has no revenues. Clinical trials but a lot of cash. SRZN has advanced trials underway for a product to treat alcoholic hepatitis presumably settling it down before it becomes irreversible cirrhosis (only for patients who are alcohol-free) and also useful for liver metabolic disorders from a genetic basis. SRZN has been...
On the weekly chart a LABU / LABD ratio is plotted with anchored VWAP bands and a volume profile overlaid. I wanted to analyze this to affirm the highest of prospects for the Biotechnology sector for 2024. LABU is triple leveraged Up while LABD is the inverse Down. A good unleveraged biotech ETF is XBI. The chart shows LABU in a VWAP band and breakout ...
FGEN has been uptrending for two weeks. In November's earnings it beat on revenue and burned less cash than projected. Another earnings report is impending. On the 30 minute chart, price has pumped 250%. The volume is okay but is not showing a rise and the price volume trend is flat. This is an unusual pattern. The mass index indicator shows hints of ...
Roivant Scientes, on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, ROIV gained 38% in 2023 but has been down 4 %YTD. The volume and volatility show both are heightened in the pre-earnings run- up. The last report...
INBS crush earnings and went parabolic on an earnings beat. Basically, revenues fell but with belt-tightening and good CEO actions it bled less cash than expected. The tourniquet is working. The post-earnings pump was followed by a flush to the mid-Fib 0.5 support. Trader's got their reward and called it a weekend before lunch. The chop index fell into the...
ZBH is a big global medical device company. It is old school. Aluminum titanium polymers, plates screws wires. Hollywood stars are familiar as it makes the devices for leg lengthening surgery. ( shortening is easy, lengthening not so much) I am familiar because in the past I have served as a consultant for this company. It business is mainly orthopedic elective...
RYTM did a 120% run in November and December and then pivoted to start the year. It competes in the anti-obesity drug space which is all the rage right now and has snack food manufactures freaking out. The retrace was a shallow one in a sign of strength finding support at the 0.382 retracement level and then pivoting into a reversal in the past week. The dual...
MGNX as a biotech company makes antibodies against certain cancers. The antibody is tagged to chemotherapy molecules and then heads off looking for cancer cells to which it has a strong affinity. So much for the science. MGNX just got upgraded and the new target is $ 16.00 about 25% upside. Biotech and healthcare are projected hot sectors this year. On the...
KRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods . A recent analyst gave it an upside to 100 which is very favorable given its product line and track record with an all-time high of about $250 ( which is about 450% over current valuation) On the one-hour time frame, it has had a great week and is breaking out over...
HRTX has been suggested by various trading websites as a potentially explosive penny biotech stock for 2024. It has experienced excellent price actions since an earnings beat in November. It beat the estimates; that is to say it burned about half as much cash as the analysts estimated the it would. Today it pumped 11%. Relevant articles can be found compiled...
Can see this at $15.00 given that is where most shares are currently held, according to FRVP; this means there will likely be little downwards price pressure until then. Biotech is generally bearish outside of select, short-lived bull runs - this, in my opinion, creates an opportunity for sentiment arbitrage and is my reasoning for the trade (short term/long term...
Reclaimed the breakdown level and now holding that level nicely. Squeeze likely to start soon and push it to at least 5.5/6 If 3.4 is lost again, could test 3.0 I am long via commons at 3.50 today. Like the risk/reward here for a double up.
as you can see this could be a huge Symmetrical triangle, like in the case of Bitcoin and S&P this means a change of trend, and a potential 120%
Moderna has had an astronomical rise due to the vaccine. The technical setup looks excellent to the short side. TD9's on the daily, 2 day, 3 day, big divergences on many timeframes. That said - there is headline risk with this - if they get FDA approval it would likely squeeze.
LABU is shown here on a 2H time frame. I am holding 500 shares having bought November 14th on golden cross of fast and slow hull moving averages. The unrealized gain is 50%. Here, I determine that I should en bloc or in increments close the position. First, on the dual time RSI indicator of Chris Moody, the RSI is now over 60 and approaching 65. Price...
ETON jumped on a big earnings report a week ago. This small cap biotechology company is making big money and traders responded. It has now experienced a standard 0.5 Fib level retracement pullback and traders early in the jump take profit. At this level new buyers have equilibrated with those selling their shares and taking profit. The ZL MACD lines are...
BIOL had a triple top in late July so this is a logical long target at 8,0, With earnings in less than two days, volumes above the mean in the past couple of days and a decent price-volume product trend coupled with a Price Monetum Oscillator without any signs of topping out in a momentum stall or fade. I see this as a long pre-earnings play with about 12%...
XYNI is now ready to reverse long. I analyze this because ZYXI has dropped from overvalued and overbought through the fair value zone into undervalued territory in three trading days by viewing the anchored VWAP bands and the volume profile, The mean VWAP and POC line are confluent at 7.25. This is the logical first target. The MACD lines are negative 4X the...